Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Add filters

Document Type
Year range
11th Italian Forum on Ambient Assisted Living, ForItAAL 2020 ; 884 LNEE:355-362, 2022.
Article in English | Scopus | ID: covidwho-2013903


Post-Covid-19 syndrome occurs in at least half survivors, that claim to suffer from a mild to severe deconditioning syndrome, fatigue, muscle wasting and pain, dizziness, very low tolerance to minimal efforts, depression and anxiety, when they not will suffer from post-critical neurological syndrome and peripheral neuropathies. Telemedicine and telerehabilitation could be decisive solutions to safely take care and follow these patients in the recovery phase, as well as to alleviate the burden of healthcare structures, in order to reach the majority of people and in the presence of the need for social distancing. The study aims at verifying the feasibility and level of users’ satisfaction of a tele-health service that provide therapeutic education protocols for people recovering from Covid-19. An average of 350 accesses per day have been registered on the platform since 31 March to 30 June 2020. 50 people answered the users’ satisfaction questionnaire and declared no side effects and a good effectiveness (median 7.5/10) to manage fatigue and anxiety. Most subjects (66%) were people hospitalized for Covid-9 and discharged home (32,6%,) or exclusively treated at home (27,6%), instead, 11,6% of subjects were still convalescent in hospital. In conclusion, tele-health was appreciated, safe and possibly useful to integrate rehabilitative management of subjects recovering from Covid-19. © 2022, The Author(s), under exclusive license to Springer Nature Switzerland AG.

Biochimica Clinica ; 45(SUPPL 2):S21, 2022.
Article in English | EMBASE | ID: covidwho-1733100


Background and Aim: Salivary SARS-CoV-2 Ab determination could be suitable for monitoring the viral spread and vaccination efficacy, especially in pediatric patients. We investigated N/S1-RBD IgG antibody levels in salivary samples of infectious-naïve vaccinated subjects and of COVID-19 patients, further comparing levels with serum anti-SARS-CoV-2 S-RBD IgG. Methods: A total of 72 subjects were enrolled at the Padova University Hospital: 36 COVID-19 patients and 36 health care workers (HCW), who underwent a complete vaccination campaign with BNT162b2 (BioNTech/Pfizer). All collected a salivary sample, using Salivette (Sarstedt, Nümbrecht Germany). For 9 HCW, salivary samples were collected at three different times within the same day (before breakfast, at 10 am, and after lunch). A serum sample was also collected for all individuals. Time post symptoms onset or time from the first vaccine were also recorded. Salivary COVID-19 N/S1 RBD (sal-IgG) ELISA (RayBiotech, GA, USA) and anti-SARS-CoV-2 S-RBD IgG Ab (ser-IgG) (Snibe Diagnostics, Shenzhen, China) were used for determining IgG Ab. Results: Subjects' mean age (±sd) was 35.8±18.2 yrs. Age significantly differed (p<0.001) from COVID-19 patients [29.7±17.3 yrs] and HCW [47.1±12.9 yrs]. Positive sal-IgG were found in 70/72 (97.2%) samples;in sera, 71/72 (98.6%) samples were positive to ser-IgG. The sal-IgG median levels differed from COVID-19 to vaccinated HCW, being in salivary samples 0.21 kAU/L and 0.8 kAU/L (p =0.030), respectively;median levels for ser-IgG in COVID-19 and vaccinated HCW were 135 kBAU/L and 940 kBAU/L, respectively (p<0.001). Salivary IgG levels were not influenced by time post-symptom onset or time post-vaccination, both on vaccinated HCW (rho= -0.147, p=0.402) and COVID-19 subjects (rho=0.0267, p=0.986). Ser-IgG levels was not influenced by the time post-symptom onset for COVID-19 subjects (rho=0.102, p=0.419), while a strong significant correlation was found with time post-vaccination in HCW (rho=-0.6292, p<0.001). Sal-IgG levels were notinfluenced by the daytime of collection (rho=0.148, p=0.373). Passing-Bablok regressions showed that sar- IgG and ser-IgG comparability was assessable only when ser-IgG values were divided by 1000, being slope and intercept 0.068 (95%CI: 0.069-0.341) and 0.221 (95%CI:- 0.097 to 0.786), respectively. Conclusions: Salivary IgG is efficiently detectable both in COVID-19 and in vaccinated individuals and analyses appeared to be not influenced by the daytime of collection. The analyses performed showed that, overall, sal-IgG were lower than ser-IgG, and thus comparability with serum levels needs to be better explored.